Your browser doesn't support javascript.
loading
Programa post-exposición a la profilaxis de la Lepra (LPEP): Actualización y análisis interno / No disponible
Steinmann, Peter; Cavaliero, Arielle; Aerts, Ann; Anand, Sunil; Arif, Mohammad; Sao Ay, Sarady; Maung Aye, Tin; Barth-Jaeggi, Tanja; Lal Banstola, Nand; Mani Bhandari, Chuda; Blaney, David; Bonenberger, Marc; Van Brakel, Wim; Cross, Hugh; Das, VK; Fahrudda, Ansarul; Fernando, Nilanthi; Gani, Zaahira; Greter, Helena; Ignotti, Eliane; Kamara, Deus; Kasang, Christa; Kömm, Burkard; Kumar, Anil; Lay, Sambath; Mieras, Liesbeth; Mirza, Fareed; Mutayoba, Beatrice; Njako, Blasdus; Pakasi, Tiara; Saunderson, Paul; Shengelia, Bakhuti; Smith, Cairns S; Stäheli, René; Suriyarachchi, Nayani; Shwe, Tin; Tiwari, Anuj; D Wijesinghe, Supun Millawage; Van Berkel, Jan; Vander Plaetse, Bart; Virmond, Marcos; Hendrik Richardus, Jan.
Afiliación
  • Steinmann, Peter; Swiss Tropical and Public Health Institute. Basel. Switzerland
  • Cavaliero, Arielle; Novartis Foundation. Basel. Switzerland
  • Aerts, Ann; Novartis Foundation. Basel. Switzerland
  • Anand, Sunil; American Leprosy Missions. Hyderabad. India
  • Arif, Mohammad; Netherlands Leprosy Relief. Hyderabad. India
  • Sao Ay, Sarady; Swiss Tropical and Public Health Institute. Phnom Penh. Cambodia
  • Maung Aye, Tin; American Leprosy Missions. Yangon. Myanmar
  • Barth-Jaeggi, Tanja; University of Basel. Basel. Swotzerland
  • Lal Banstola, Nand; Netherlands Leprosy Relief. Kathmandu. Nepal
  • Mani Bhandari, Chuda; Department of Health Services. Kathmandu. Nepal
  • Blaney, David; Centers for Disease Control and Prevention. Atlanta. USA
  • Bonenberger, Marc; FAIRMED, Bern. Switzerland
  • Van Brakel, Wim; Netherlands Leprosy Relief. Amsterdam. The Netherlands
  • Cross, Hugh; s.af
  • Das, VK; Health Services. Dadra and Nagar Haveli. India
  • Fahrudda, Ansarul; East Java Provincial Health Office. Indonesia
  • Fernando, Nilanthi; Anti-Leprosy Campaign. Colombo. Srik Lanka
  • Gani, Zaahira; Novartis Foundation. Basel. Switzerland
  • Greter, Helena; University of Basel. Basel. Switzerland
  • Ignotti, Eliane; Universidade do Estado de Mato Grosso. Cáceres. Brasil
  • Kamara, Deus; National Tuberculosis and Leprosy Programmeme. Dar es Salaam. Tanzania
  • Kasang, Christa; German Leprosy and Tuberculosis Relief Association. Würzburg. Germany
  • Kömm, Burkard; German Leprosy and Tuberculosis Relief Association. Würzburg. Germany
  • Kumar, Anil; MoHFW. Directorate General of Health Services. New Delhi. India
  • Lay, Sambath; National Leprosy Elimination Programme. Phnom Penh. Cambodia
  • Mieras, Liesbeth; Netherlands Leprosy Relief. Amsterdam. The Netherlands
  • Mirza, Fareed; Novartis Foundation. Basel. Switzerland
  • Mutayoba, Beatrice; National Tuberculosis and Leprosy Programmeme. Dar es Salaam. Tanzania
  • Njako, Blasdus; German Leprosy and Tuberculosis Relief Association. Dar es Salaam. Tanzania
  • Pakasi, Tiara; MoH. Jakarta. Indonesia
  • Saunderson, Paul; American Leprosy. Aberdeen. United Kingdom
  • Shengelia, Bakhuti; Novartis Foundation. Basel. Switzerland
  • Smith, Cairns S; University of Aberdeen. Aberdeen. United Kingdom
  • Stäheli, René; FAIRMED. Bern. Switzerland
  • Suriyarachchi, Nayani; FAIRMED. Aberdeem. United Kingdom
  • Shwe, Tin; American Leprosy Missions. Yangon. Myanmar
  • Tiwari, Anuj; University Medical Center Rotterdam. Rotterdam. The Netherlands
  • D Wijesinghe, Supun Millawage; Anti-Leprosy Campaign. Colombo. Srik Lanka
  • Van Berkel, Jan; Netherlands Leprosy Relief. Amsterdam. The Netherlands
  • Vander Plaetse, Bart; FAIRMED, Bern. Switzerland
  • Virmond, Marcos; Institute Lauro de Souza Lima. Bauru. Brazil
  • Hendrik Richardus, Jan; University Medical Center Rotterdam. Rotterdam. The Netherlands
Fontilles, Rev. leprol ; 31(5): 375-393, mayo-ago. 2018. ilus, tab, graf
Article en Es | IBECS | ID: ibc-175731
Biblioteca responsable: ES1.1
Ubicación: BNCS
RESUMEN
Se requieren nuevos planteamientos para incrementar el control de la lepra, disminuir el número de personas afectadas y cortar la transmisión. Para conseguir este objetivo las mejores soluciones son la detección precoz. El cribaje de contactos y la quimioprofilaxis. El Programa Profilaxis Post-exposición a la Lepra (LPEP) ayuda a demostrar la viabilidad de integrar el rastreo de contactos y dosis única de rifampicina (SDR) en las actividades rutinarias de control de la enfermedad. El programa LPEP está implementado entre los programas de control de la lepra de Brasil, Camboya, India, Indonesia, Myanmar, Nepal, Sri Lanka y Tanzania. Se centra en tres objetivos: rastro de contactos de nuevos pacientes diagnosticados de lepra, cribaje de contactos y administración de SDR a los contactos seleccionados. Las adaptaciones de protocolos países-específicos se refieren a la definición de contacto, edad mínima para SDR y personal implicado. La calidad de la evidencia se mantiene mediante coordinación central, documentación detallada y supervisión. Ya se han completado alrededor de 2 años de trabajo de campo en siete países en julio de 2017. Los 5,941 pacientes índice registrados (89·4% de los registrados) han identificado un total de 123,311 contactos, de los cuales el 99·1% ha sido rastreado y cribado. De entre ellos, se identificaron 406 nuevos pacientes de lepra (329/100,000) y a 10,883 (8·9%) no se les administró SDR por diversos motivos. También 785 contactos (6·7%) rehusó tomar la profilaxis con SDR. En total, se administró SDR al 89·0% de los contactos registrados. La profilaxis post-exposición con SDR es segura; se puede integrar en los programas rutinarios de control de la lepra y es generalmente bien aceptada por el paciente índice, sus contactos y el personal sanitario. El programa también consigue estimular los programas locales de control de la lepra
ABSTRACT
Innovative approaches are required to further enhance leprosy control, reduce the number of people developing leprosy, and curb transmission. Early case detection, contact screening, and chemoprophylaxis currently is the most promising approach to achieve this goal. The Leprosy Post-Exposure Prophylaxis (LPEP) programme generates evidence on the feasibility of integrating contact tracing and single-dose rifampicin (SDR) administration into routine leprosy control activities in different settings. The LPEP programme is implemented within the leprosy control programmes of Brazil, Cambodia, India, Indonesia, Myanmar, Nepal, Sri Lanka and Tanzania. Focus is on three key interventions: tracing the contacts of newly diagnosed leprosy patients; screening the contacts for leprosy; and administering SDR to eligible contacts. Country-specific protocol adaptations refer to contact definition, minimal age for SDR, and staff involved. Central coordination, detailed documentation and rigorous supervision ensure quality evidence. Around 2 years of field work had been completed in seven countries by July 2017. The 5,941 enrolled index patients (89·4% of the registered) identified a total of 123,311 contacts, of which 99·1% were traced and screened. Among them, 406 new leprosy patients were identified (329/100,000), and 10,883 (8·9%) were excluded from SDR for various reasons. Also, 785 contacts (0·7%) refused the prophylactic treatment with SDR. Overall, SDR was administered to 89·0% of the listed contacts. Post-exposure prophylaxis with SDR is safe; can be integrated into the routines of different leprosy control programmes; and is generally well accepted by index patients, their contacts and the health workforce. The programme has also invigorated local leprosy control
Asunto(s)
Texto completo: 1 Colección: 06-national / ES Base de datos: IBECS Asunto principal: Rifampin / Asunción de Riesgos / Diagnóstico Precoz / Profilaxis Posexposición / Lepra Tipo de estudio: Diagnostic_studies / Etiology_studies / Guideline / Screening_studies Límite: Humans Idioma: Es Revista: Fontilles, Rev. leprol Año: 2018 Tipo del documento: Article
Texto completo: 1 Colección: 06-national / ES Base de datos: IBECS Asunto principal: Rifampin / Asunción de Riesgos / Diagnóstico Precoz / Profilaxis Posexposición / Lepra Tipo de estudio: Diagnostic_studies / Etiology_studies / Guideline / Screening_studies Límite: Humans Idioma: Es Revista: Fontilles, Rev. leprol Año: 2018 Tipo del documento: Article